Kaiser, P K <br/><br/>
Verteporfin photodynamic therapy and anti-angiogenic drugs: potential for combination therapy in exudative age-related macular degeneration.  [electronic resource] 

 -  Current medical research and opinion  Mar 2007 
 - 477-87 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review 
<br/><br/><label>ISSN: </label>1473-4877 
<br/><br/><label>Standard No.: </label>10.1185/030079907X167624  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Age Factors<br/>Aged<br/>Angiogenesis Inhibitors--therapeutic use<br/>Animals<br/>Antibodies, Monoclonal--therapeutic use<br/>Antibodies, Monoclonal, Humanized<br/>Aptamers, Nucleotide--therapeutic use<br/>Choroidal Neovascularization--diagnosis<br/>Clinical Trials, Phase II as Topic<br/>Clinical Trials, Phase III as Topic<br/>Disease Models, Animal<br/>Dose-Response Relationship, Drug<br/>Drug Administration Schedule<br/>Drug Therapy, Combination<br/>Female<br/>Haplorhini<br/>Humans<br/>Macular Degeneration--drug therapy<br/>Male<br/>Middle Aged<br/>Photochemotherapy--methods<br/>Porphyrins--therapeutic use<br/>Prognosis<br/>Ranibizumab<br/>Risk Assessment<br/>Treatment Outcome<br/>Verteporfin<br/>Visual Acuity